| | | | | | | Но | ome Sitemap | Search Cont | act Us | |
|------------------------|-----------------------|---|---|---|--|--|--|--------------|-------------------------|-------|
| About the Institute | News & Information | Policies & Guidelines | Occupational Health & Safety | Clinical Research | Clinical Research Unit | Grants & Education | Investigators Database | For Trainees | Donating to Research | Links |
| EWS & INI | FORMATION | | | | | | | | | |
| ws Releases | 5 | Tue Feb 2 | 23 2010 | | | | | | | |
| 10 | | Scientists | generate promisin will respond to diff | | el for predicting h | ow individual lu | ing | | | |
|)9)8 | | BC C | ancer Agency | | MED] | Λ | | | | |
|)7 | | An agency of | the Provincial Realth Services Authority | | | | DV | | | |
|)6 | | | lealth h Institute | KELE | ASE FE | | KT | | | |
|)5 | | Healthier lives th | trough discovery | | 23, 20 | 10 | | | | |
|)4 umphs, Hon | ours & Awards | _{ Ser | | | te promising new tumours will res | | | | | |
| 10 | | | BRITISH Vanco | | Scientists at the BC Health Research Ins | | | | | |
| 09 | | | The Best Place on Earth faster | identification | hod that may one of which chemothe | rapy regimens m | ay be useful | | | |
| 8 | | to be effect | g a particular patient tive. | 's non-small (| cell lung cancer (NS | CLC) and which a | are unlikely | | | |
| 17 16 | | | s of their experiment he international jourr | | | | | | | |
|)5 | | samples fr | on in a model xenogra om 32 patients to th | ree different (| chemotherapy regin | nens. The respons | ses | | | |
|)4 | | model, sor | n the model were the ne cancers were resin six of seven cases | stant to a par | ticular treatment re | gimen but sensit | ive to | | | |
| 13 | | as that ap | plied clinically, the so related with the clinic | ientists were | able to show that t | he results obtaine | ed in the | | | |
| wsletters | | | eight weeks to com test if further validat | | could be rapid enou | gh to be useful a | s a | | | |
| ghlights of P | ast Events | "I am very excited that something we developed here in the lab might have a clinical application to help physicians determine the best treatment option for their patients in the future," said Yuzhuo Wang, PhD, Senior Scientist whose group performed these studies as part of a joint initiative of the BC Cancer Agency and Vancouver Prostate Centre. "And while this particular study focused on lung cancer, I believe the method could be expanded to cover other major cancers as well." | | | | | | | | |
| | | Lung cancer is the leading cause of cancer-related deaths worldwide and NSCLC accounts for more than 80 per cent of these deaths. Nearly 3,000 British Columbians will be diagnosed with lung cancer this year and more than 2,400 will die of it, approximately seven people every day. Chemotherapy has been shown to improve the survival of some patients with NSCLC; but many of these cancers respond poorly to the treatments currently available. Due to the high toxicity of these treatments, additional treatments are often not possible if the first is not successful. | | | | | | | | |
| | | "When someone is diagnosed with lung cancer we discuss with them whether treatment is appropriate, and if it is, which treatment we think would be most likely to be effective for them based on our clinical experience," said Dr. Stephen Lam, Chair of the Lung Tumour Group and Senior Scientist at the BC Cancer Agency, and a physician in the Lung Centre at Vancouver General Hospital. "This discovery gives me hope that someday I may have a diagnostic test available that will assist me in predicting and recommending the most effective course of treatment for my patients." | | | | | | | | |
| | | Grant support for the research was provided by Genome Canada and the BC Cancer Foundation. | | | | | | | | |
| | | "The BC Cancer Foundation funds research such as Dr. Wang's, at the BC Cancer Agency as the results deliver great hope for cancer patients and their families throughout B.C. and beyond," said Douglas Nelson, President & CEO of the BC Cancer Foundation. "While lung cancer remains the leading cause of cancer death, one of our reasons for great optimism is this effort to move towards a more effective personalized medicine approach where clinicians will be able to select the most effective treatments for individual cases." | | | | | | | | |
| | | committed improving control pro deliver a r treatment, Cancer Fou | the reducing the incit the quality of life of ogram for the people ange of oncology ser research, education undation raises funda neer Agency. www.br | dence of cance those living w of British Col vices, includir , supportive c to support r | er, reducing the mo vith cancer. It provio umbia by working v ng prevention, early are, rehabilitation a | rtality from cance des a comprehens vith community p detection, diagn nd palliative care | er, and sive cancer artners to osis and . The BC | | | |
| | | sciences re institute is the Univer including t | buver Coastal Healt asearch centres, with the research arm of sity of British Columi he Vancouver Prosta I Mobility. For more, | \$102.5 millio Vancouver Co bia, and encon te Centre; the | on in total research bastal Health Author mpasses world reco Brain Research Ce | funding for 2008/ rity and a health gnized research c | 2009. The partner of entres | | | |

For more information or to arrange an interview, please contact:

Rob McMahon Communications Specialist BC Cancer Agency Tel: 604.877.6272 Cell: 604.230.1463 Toll-free: 1.800.663.3333, ext 6272 rmcmahon@cw.bc.ca

Lisa Carver Regional Communications Leader VCH Research Institute Tel: 604.875.4111 ext 61777 Cell: 604.319.7533 <u>lisa.carver@vch.ca</u>

You can view the **<u>Previous</u>** News Releases item: Mon Feb 8, 2010, Marijuana ineffective as an Alzheimer's treatment: UBC-Vancouver Coastal Health research

You can return to the main $\underline{\mbox{News Releases}}$ page, or press the \mbox{Back} button on your browser.